New:
-
Dr. Lara Davis, OHSU physician, researcher shares her research: Discovery and characterization of novel, recurrent, targetable ALK fusions in leiomyosarcoma
The result of this research provides the first validation of a targetable oncogenic kinase fusion as a driver in a subset of leiomyosarcomas. Overall, these findings suggest that some soft tissue sarcomas may harbor previously unknown kinase gene translocations, and their discovery may propel new therapeutic strategies in this treatment-refractory cancer. - Discovery and characterization of recurrent, targetable ALK fusions in leiomyosarcoma
- Trabectedin, Doxorubicin, and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma
- Cancer research stories from Stanford Medicine and the Stanford Cancer Institute
Read about cancer research from Stanford Medicine’s News & Publications
Twitter updates available @StanfordCancer
- In select sarcoma subtypes, researchers determined the disease control rate (DCR) with sorafenib plus dacarbazine. They examined patients with leiomyosarcoma (LMS), synovial sarcoma (SS), or malignant peripheral nerve sheath tumors (MPNST) with up to two previous lines of therapy and adequate hepatic, renal, and marrow function. Treatment regimen for these subjects comprised 3-week cycles of sorafenib at 400 mg oral twice daily and dacarbazine 1,000 mg/m2 intravenously (later reduced to 850 mg/m2). An 18-week DCR of 46% was documented in this study. Modest clinical activity of dacarbazine + sorafenib was evident in patients with these diagnoses. Dacarbazine + sorafenib was feasible and related to favorable disease-control rates; however, this combination also increased the potential for significant toxicity. Read the full article on The Oncologist
one NTRK fusion and it was very exciting.” – from Dr. Neeta Somaiah, MD, Sarcoma Research, Anderson Cancer Center.
A phase II study of tumor ablation in patients with metastatic sarcoma stable on chemotherapy
A vimentin binding small molecule leads to mitotic disruption in mesenchymal cancers
Adjuvant Therapy Does Not Improve Survival for Early Stage Uterine Leiomyosarcoma
Cancer ‘vaccine’ eliminates tumors in mice
Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma
Mocetinostat combined with gemcitabine for the treatment of leiomyosarcoma: Preclinical correlates
Next-generation sequencing for patients with sarcoma: A single center experience
Nivolumab With Ipilimumab Promising for Pretreated Metastatic Sarcoma
Options for Adjuvant Therapy for Uterine Leiomyosarcoma
Soft Tissue and Uterine Leiomyosarcoma
Leiomyosarcoma Articles by Dr. Alexander Lazar:
Dr. Alexander Lazar (medical advisory council member) is a research pathologist from MD Anderson Cancer Center in Houston, Texas.
Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas
Clinical Observations and Molecular Variables of Primary Vascular Leiomyosarcoma
Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas
Progressive loss of myogenic differentiation in leiomyosarcoma has prognostic value